POM, the Nasdaq-listed Pomdoctor Limited, enters the week caught between a sharp one-month rally and a sudden surge in short positioning that has pushed borrow costs to levels rarely seen in small-cap healthcare.
The most striking feature of this week's setup is the speed of the short rebuild. Short interest tripled over a five-day window, jumping roughly 200% week-on-week to around 634,000 shares. That leaves SI at approximately 0.5% of the float by ORTEX daily estimate — small in absolute terms, but the velocity of the move is hard to ignore on a stock with a market cap of just $47 million. The shares short peaked above 800,000 on April 29 before easing back, suggesting some covering into last week's close.
Cost to borrow tells a different story about how tight the lending market has become. At 53.1% annually, borrowing is far from cheap — and the rate hit 73% as recently as April 30, the highest reading in the past six weeks. The one-week rise in CTB is 12%, and the one-month gain is nearly 17%. Availability, however, is running at roughly 178% of current short interest, meaning there is still meaningful supply in the lending pool relative to demand. That availability cushion rules out acute squeeze pressure for now, even as the borrow price itself remains elevated. The 52-week high for availability has touched 100% utilization in the past, suggesting this stock can go through extended tight-borrow episodes.
The ORTEX short score adds colour to the shift. It climbed from 42.9 on April 22 to 62.7 on April 29 — a significant re-rating in positioning risk over less than two weeks — before easing slightly to 58.4 by May 5. The DTC rank is at the 67th percentile, meaning the stock takes longer to cover than most of its peers. Utilization rank is at the 20th percentile, consistent with the relatively comfortable availability reading. The combined picture is one of increasing short conviction that has not yet reached the extremes that would produce a forced unwind.
The ownership structure warrants attention. The top two identified holders — Zhenyang Shi with 17.8% and Xianyang Buchang Pharmaceutical with 14.98% — are Chinese entities, and together with Focus Media and Beijing Gaotejia they account for over 49% of shares. The float available to short sellers is thin as a result. That concentration amplifies the impact of even modest short flows, which explains why a relatively small absolute position can still move the needle on borrow metrics and stock price.
On price, POM is up 61% over the past month despite slipping 6% in the past week. The one-day reading recovered 3.8% on May 5. The nearest correlated peer, ATPC, gained 25% on the week — a sharp divergence. NIVF moved the other way, falling 23% over the same period. The split in peer performance makes it hard to read a clean sector theme, pointing instead to stock-specific flows driving POM's tape.
The two earnings events on record show the stock can move sharply around catalysts: a 10.8% one-day gain in April 2026 and a 1.7% move in December 2025. No next earnings date is currently confirmed. What to watch is whether the short rebuild continues past the 800,000-share peak seen late April, and whether the CTB stays above 50% as availability narrows — those two signals together would mark a meaningful escalation in the positioning story.
See the live data behind this article on ORTEX.
Open POM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
